Regulators hit Wall Road banking institutions with $549 million in penalties for history-trying to keep failures

Regulators hit Wall Road banking institutions with 9 million in penalties for history-trying to keep failures


Crucial Points
  • U.S. regulators on Tuesday announced a combined $549 million in penalties from Wall Avenue corporations that failed to retain digital information of worker communications.
  • The Securities and Trade Fee announced expenses and $289 million in fines against 11 corporations for “common and longstanding failures” to keep records, together with by enabling workers to use unsupervised aspect channels such as messaging applications WhatsApp and Signal, the regulator said.
  • The Commodity Futures Trading Commission also said it fined 4 banks a whole of $260 million for failing to sustain information needed by the agency.



Supply

Here are 3 forces that drove the stock market during Wall Street’s comeback week
Finance

Here are 3 forces that drove the stock market during Wall Street’s comeback week

The stock market staged a comeback last week, even as Wall Street waded through a flurry of both upbeat and unsettling headlines. The Nasdaq broke its five-week losing streak on Friday, buoyed by strong advances from our big tech names like Meta Platforms , Nvidia and Amazon . The tech-heavy index ended the week 1.9% […]

Read More
Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’
Finance

Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’

ETF Edge Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’ Published Sat, Feb 21 202611:00 AM EST Blair Bao WATCH LIVE Source

Read More
Stocks making the biggest moves premarket: Grail, Blue Owl Capital, Opendoor Technologies & more
Finance

Stocks making the biggest moves premarket: Grail, Blue Owl Capital, Opendoor Technologies & more

Check out the companies making headlines before the bell. Grail — Shares cratered 47% after the company said a trial of one of its drugs missed its primary endpoint and failed to show statistically significant Stage III-IV cancer reduction. Blue Owl Capital — Shares slid nearly 3%, a day after after the private market and […]

Read More